Journal
CLINICAL INFECTIOUS DISEASES
Volume 61, Issue 12, Pages 1835-1838Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/civ686
Keywords
pneumococcal conjugate vaccine; community-acquired pneumonia; invasive pneumococcal disease; vaccine efficacy; immunosenescence
Categories
Ask authors/readers for more resources
In a post hoc analysis of the Community-Acquired Pneumonia (CAP) immunization Trial in Adults the model-predicted 13-valent pneumococcal conjugate vaccine efficacy for preventing vaccine-type specific CAP and Invasive Pneumococcal Disease declined from 65% to 40% for subjects being 65 and 75 year olds at the time of vaccination, respectively.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
